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Fanconi anemia (FA) is a rare bone marrow failure
and cancer predisposition syndrome resulting from
pathogenic mutations in genes encoding proteins
participating in the repair of DNA interstrand cross-
links (ICLs). Mutations in 17 genes (FANCA-FANCS)
have been identified in FA patients, defining 17
complementation groups. Here, we describe an
individual presenting with typical FA features who
is deficient for the ubiquitin-conjugating enzyme
(E2), UBE2T. UBE2T is known to interact with FANCL,
the E3 ubiquitin-ligase component of themultiprotein
FA core complex, and is necessary for the monoubi-
quitination of FANCD2 and FANCI. Proband fibro-
blasts do not display FANCD2 and FANCI monoubi-
quitination, do not form FANCD2 foci following
treatment with mitomycin C, and are hypersensitive
to crosslinking agents. These cellular defects are
complemented by expression of wild-type UBE2T,
demonstrating that deficiency of the protein UBE2T
can lead to Fanconi anemia. UBE2T gene gains an
alias of FANCT.
INTRODUCTION
Fanconi anemia (FA) is a rare disorder characterized by develop-
mental abnormalities, bone marrow failure in the first decade of
life, predisposition to solid tumors and leukemia, and cellular
hypersensitivity to crosslinking agents (Auerbach, 2009). FA
results from biallelic mutations in genes encoding proteins
important for the repair of DNA interstrand crosslinks (ICLs).
Patient mutations have been identified in 17 FA genes(FANCA-FANCS), whereas a minority of patients have unknown
causative gene mutations (Kottemann and Smogorzewska,
2013; Sawyer et al., 2015; Wang and Smogorzewska, 2015).
DNA ICLs are deleterious DNA lesions that covalently link
DNA strands blocking transcription and replication. Com-
pounds such as mitomycin C (MMC), diepoxybutane (DEB),
cisplatin, and nitrogen mustards can generate ICLs, whereas
naturally occurring biological metabolites such as aldehydes
are suspected to cause endogenous lesions (Garaycoechea
et al., 2012; Hira et al., 2013; Langevin et al., 2011; Ridpath
et al., 2007). Diagnosis of FA is made based on chromosomal
breakage assays using crosslinking agents DEB or MMC
(Auerbach, 1993). FA patient cells show increased breakage
levels when challenged with crosslinking agents compared to
normal cells.
During DNA replication, ICLs cause replication fork stalling
and activation of the FA pathway (Garcia-Higuera et al., 2001;
Knipscheer et al., 2009). Removal of ICLs is a multistep process
requiring activation of the FA core complex composed of eight
FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG,
FANCL, and FANCM) and their interacting factors. A key step in
ICL repair is the core-complex-mediated monoubiquitination of
FANCD2 and FANCI (Dorsman et al., 2007; Garcia-Higuera
et al., 2001; Sims et al., 2007; Smogorzewska et al., 2007;
Timmers et al., 2001). Ubiquitin transfer requires the activity of
an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating
enzyme, and an E3 ubiquitin-ligating enzyme (reviewed in
Hershko and Ciechanover, 1998). The FANCL subunit of the
FA core complex is the E3 ubiquitin-ligase that monoubiquiti-
nates FANCD2 and FANCI (Meetei et al., 2003). UBE2T has
been identified as the E2 ubiquitin-conjugating enzyme, and its
interaction with FANCL is required for monoubiquitination of
FANCD2 and FANCI (Alpi et al., 2008; Hodson et al., 2014;
Longerich et al., 2009; Machida et al., 2006; Rajendra et al.,
2014; Sato et al., 2012). A second E2, UBE2W, has beenCell Reports 12, 35–41, July 7, 2015 ª2015 The Authors 35
described to interact with FANCL and ubiquitinate FANCD2
in vitro, but the physiological importance of this interaction has
not been explored in mammalian cells (Alpi et al., 2008; Rajendra
et al., 2014; Zhang et al., 2011).
Activated FANCD2 and FANCI form the ID2 complex that
localizes to chromatin and is required for coordinating repair at
the crosslink (Garcia-Higuera et al., 2001; Knipscheer et al.,
2009; Smogorzewska et al., 2007). Processing of the ICL encom-
passes nucleolytic unhooking of the crosslink that is dependent
on FANCP/SLX4 and ERCC4/FANCQ/XPF, translesion synthesis
bypass of the unhooked ICL on one strand, and double-strand
break (DSB) repair by homologous recombination (HR) on the
other strand (Kim et al., 2011, 2013; Klein Douwel et al., 2014;
Long et al., 2011; Niedernhofer et al., 2004; Tischkowitz et al.,
2007; Xia et al., 2007).
Here, we describe an individual enrolled in the International
Fanconi Anemia Registry (IFAR) presenting with typical FA
features and deficiency of the ubiquitin-conjugating enzyme
(E2), UBE2T. Sanger sequencing of genomic DNA revealed a
large paternal deletion and maternal duplication resulting from
Alu-mediated recombination. In the absence of UBE2T expres-
sion, the proband cells are defective for FANCD2 and FANCI
monoubiquitination, do not form FANCD2 foci following treat-
ment with MMC, and are hypersensitive to crosslinking agents.
These cellular defects are complemented by expression of
wild-type UBE2T, demonstrating that deficiency of the protein
UBE2T can cause FA.
RESULTS
Cellular Phenotype of FA Cell Line of Unknown
Complementation Group
The subject presented at birth with bilateral radial aplasia,
absent thumbs, microcephaly, micrognathia, cafe´ au lait spots,
absent left kidney (Table S1), and elevated chromosomal
breakage in peripheral blood samples treated with DEB. Periph-
eral blood samples tested over the years displayed decreasing
chromosomal breakage levels and increasing evidence of
somatic mosaicism in the hematopoietic compartment, a
phenomenon seen in a small subset of FA patients (Table S2)
(Gregory et al., 2001; Lo Ten Foe et al., 1997; Waisfisz et al.,
1999). The subject has not developed bone marrow failure at
the age of 16.
Fibroblasts derived from the subject (RA2627) are hypersensi-
tive to crosslinking agents MMC and DEB in survival assays (Fig-
ures 1A and 1B). Chromosomal breakage levels are elevated
in RA2627 fibroblasts treated with DEB as compared to BJ
wild-type fibroblast, although slightly lower than FA-A patient
cells (RA3087; Figures 1C and 1D). RA2627 cells are deficient
for FANCD2 monoubiquitination (Figure 1E) whereas the lym-
phoblastoid cell line (LCL; RA2946) derived from blood that
showed mosaicism, displays normal FANCD2 monoubiquitina-
tion (Figure 1F). By immunofluorescence, FANCD2 foci were
not observed in RA2627 cells following 24-hr treatment with
MMC (Figure 1G). These data demonstrate that the subject’s
fibroblasts display deficiency of FA pathway activation, consis-
tent with the deficiency of the FA core complex, one of the
associated proteins, or the ID2 complex, whereas the subject’s36 Cell Reports 12, 35–41, July 7, 2015 ª2015 The AuthorsLCLs are phenotypically reverted consistent with mosaicism
observed in subject’s blood.
Whole-Exome Sequencing and High-Resolution Array
Comparative Genomic Hybridization
High-resolution array comparative genomic hybridization
(aCGH) of genomic DNA from the subject’s fibroblasts and pe-
ripheral blood samples did not detect deletions or duplications
in the known FA genes (Table S3). Whole-exome sequencing
(WES) of DNA derived from proband LCLs and parental periph-
eral blood samples was performed. Analysis of WES data re-
vealed a single FANCA mutation, c.2574C > G/p.Ser858Arg,
previously described in FA (Wijker et al., 1999). Normal levels
of FANCA were detected by western blot in RA2627 cells (Fig-
ure 2A), and overexpression of wild-type FANCA in RA2627
failed to rescue the monoubiquitination defect of FANCD2 and
FANCI, excluding FANCA as a causative gene in this cell line
(Figures 2B and 2C). WES analysis identified no other mutations
in reported FA genes.
Identification of Biallelic UBE2T Mutations
in the Subject
RNA sequencing (RNA-seq) was performed on RA2627 fibro-
blasts to assess altered transcript levels that might indicate
functionally significant gene mutations not captured by WES.
Compared to a non-FA patient cell line (RA3380), a marked
reduction in UBE2T was detected, but not for any of the known
FA genes (Figure 3A). Decreased UBE2T transcript levels were
confirmed by qRT-PCR (Figure 3B), and UBE2T protein was un-
detectable in RA2627 fibroblast lysates (Figure 3C). However,
UBE2T transcript and protein were present at near normal levels
in proband LCLs (RA2946; Figures 3B and 3D), supporting
the presence of a genetic reversion in the hematopoietic
compartment.
Sanger sequencing of genomic DNA and cDNA from proband
primary fibroblasts, parental peripheral blood, andLCLs revealed
compound heterozygous mutations in UBE2T (Figures 3E, S1,
and S2; see also Supplemental Experimental Procedures).
The paternally derived deletion, g.202332626_202341295 del,
appears to have resulted from recombination of two AluYa5
repeats within the UBE2T gene (Figure S1). This deletion is ex-
pected to be a null allele, as it results in the loss of a majority of
the gene, including the start codon.
The maternal duplication, g.202332626_202341295 dup, also
appears to be mediated by Alu recombination. The maternally
derived mutation consists of a large duplication of the genomic
region between the two AluYa5 repeats (Figures 3E and S2).
Cloning of proband cDNA revealed a transcript containing the
hypothesized duplication c.-64_468 dup (dupEx2_6; Figures
3E, S2D, and S2E). In this transcript, exon 6 is spliced to the
duplicated exon 2. Inclusion of the noncoding region from
exon 2 results in a frameshift and a premature stop codon. The
c.-64_468 dup transcript can be detected at very low frequency
in RA2627 cells and is likely degraded by nonsense-mediated
decay due to the premature stop codon. If any transcript is
translated, it may produce a residual amount of the predicted
protein p.A157Cfs*7 (Figures 3E and S2). The maternally derived




Figure 1. Characterization of Cell Lines from an Individual with FA under Study
(A and B) MMC and DEB cell survival assays of the subject’s RA2627 fibroblasts in comparison to FANCAmutant and BJ wild-type fibroblasts. Cells were treated
in triplicate with increasing concentration of MMC or DEB. Cell numbers were determined after 7 days and normalized to untreated control to give percent
survival. Error bars represent SD.
(C) Example of metaphase spread of RA2627 following 0.1 mg/ml DEB treatment. Inset images emphasize radial chromosomes.
(D) Quantification of chromosome breaks of DEB-treated BJ, FANCAmutant, and RA2627 fibroblasts. Mean breaks per cell were 0.19, 7.5, and 3.3, respectively.
(E and F) Western blot with FANCD2 antibody of BJ, RA2627 proband fibroblasts, and FANCA mutant fibroblasts or non-FA control RA2987 lymphoblasts,
RA2946 proband lymphoblasts, and FANCA mutant lymphoblasts. Cells were cultured with or without 1 mM MMC for 24 hr.
(G) FANCD2 foci formation following treatment with or without 1 mM MMC for 24 hr.the expression of wild-type UBE2T in the proband blood
may be due to recombination of the maternally derived allele
(Figure S2A).
Complementation of RA2627 Cellular Defects by Wild-
Type UBE2T Expression
To prove that UBE2T deficiency is the cause of the subject’s
FA, we introduced wild-type UBE2T into RA2627 fibroblasts
and assayed for rescue of FA phenotypes. Overexpression of
UBE2T rescued cellular hypersensitivity to crosslinking agents
MMC, DEB, and cisplatin (Figures 4A–4C). Analysis of cell-cycle
distribution following treatment with MMC revealed an accumu-
lation of RA2627 cells in G2 that was rescued by UBE2T overex-
pression to the levels observed in wild-type BJ cells (Figure 4D).
UBE2T expression restored monoubiquitination of FANCD2 and
FANCI (Figure 4F) and FANCD2 foci following treatment withMMC (Figure 4G). These results confirm that deficiency of
UBE2T results in FA-T subtype.
DISCUSSION
In this study, we have identified a FA subtype resulting from
deficiency of UBE2T. Analysis of RNA-seq data was critical
in identifying UBE2T deficiency, stressing that multipronged
diagnostic approaches are often necessary in a genetically het-
erogeneous disease like FA.
We have identified compound heterozygous mutations in
UBE2T, a large genomic deletion in the paternally derived allele,
and a large duplication in the maternally derived allele. Both of
the mutations appear to be driven by Alu-mediated non-allelic
homologous recombination (NAHR). NAHR is a prevalent mech-
anism in genetic disorders arising from copy-number defectsCell Reports 12, 35–41, July 7, 2015 ª2015 The Authors 37
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Figure 2. FANCA cDNA Fails to Complement RA2627 FANCD2
and FANCI Monoubiquitination Defect
(A) Western blot with FANCA antibody of RA2627, BJ, and FANCA mutant
fibroblasts.
(B) Expression of wild-type HA-FLAG-tagged FANCA cDNA or empty vector
control (EV) in RA2627 and FANCA mutant fibroblasts.
(C) Western blot with FANCD2 and FANCI antibody of FANCA-complemented
cells.due to recurrent intrachromosomal recombination events
(reviewed in Deininger, 2011). Recently, sequencing of FANCA
deletion variants identified that breakpoints preferentially lie
within Alu elements and has revealed NAHR as a major mecha-
nism of deletion in FANCA (Flynn et al., 2014).
The subject presented at birth with classic FA features
including developmental defects and increased chromosomal
breakage. The subject has not yet developed bone marrow
failure at the age of 16. Blood counts are likely preserved due
to the somatic mosaicism of the hematopoietic compartment.
Restoration of UBE2T expression is detected in the individual’s
lymphoblast cells, and we have observed increasing rescue
of chromosomal breakage in peripheral blood since birth. The
subject’s bone marrow remains stable but hypocellular for age
(30%–40%), and it is unclear whether mosaicism will continue
to improve the bone marrow cellularity.
The paternally derived deletion mutation is expected to not
produce protein due to deletion of the majority of the coding re-
gion and start codon, whereas thematernally derived duplication
results in very low levels of the c.-64_468 dup UBE2T transcript.
This transcript may theoretically produce a UBE2T p.A157Cfs*7
protein, but it is clearly insufficient to fully support FA pathway
function as evident by the phenotype of the subject and the
cellular defects. The subject’s fibroblasts are as sensitive as
FA-A patient cells by cell survival assay, and no monoubiquitina-
tion of FANCD2 or FANCI is detected. However, breakage levels38 Cell Reports 12, 35–41, July 7, 2015 ª2015 The Authorsare not as elevated as control FA-A fibroblasts, leaving the
possibility that residual truncated UBE2T may be present and
active at a very low level, affecting the breakage phenotype.
An alternative explanation could be the presence of another E2
with low levels of activity.
UBE2T has been demonstrated to be the major E2 ubiquitin-
conjugating enzyme required for the monoubiquitination of
FANCD2 and FANCI (Alpi et al., 2008; Hodson et al., 2014; Lon-
gerich et al., 2009, 2014; Machida et al., 2006; Sato et al., 2012).
Efficient and specific FANCD2 monoubiquitination in vitro by
UBE2T/FANCL requires the presence of FANCI and DNA (Lon-
gerich et al., 2014; Sato et al., 2012). In vitro studies have demon-
strated that a second E2, UBE2W, can also ubiquitinate FANCD2
(Alpi et al., 2008; Zhang et al., 2011). In recent work, the in vitro
monoubiquitination of FAND2 by UBE2W is demonstrated to
be nonspecific, does not require interaction of ID2 complex,
and is not stimulated by DNA (Rajendra et al., 2014). Additionally,
DUBE2W chicken DT40 cells do not display sensitivity to MMC
and display normal levels of MMC-induced monoubiquitination
of FANCD2 (Rajendra et al., 2014).
Our identification of biallelic UBE2T mutations and UBE2T
deficiency in an individual with FA corroborates that UBE2T is
the primary E2 of the FA pathway required for the activation of
the ID2 complex and repair of DNA ICLs. Deficiency of UBE2T
causes FA-T disease subtype, and FANCT will be the alias for
UBE2T. Future evaluation of FA patients with unknown gene
mutations should include complementation studies of UBE2T.
EXPERIMENTAL PROCEDURES
Study Subject/Cell Lines
DNA samples and cell lines were derived from subjects enrolled in the IFAR
after obtaining informed written consent. The Institutional Review Board of
The Rockefeller University approved these studies.
Cell Culture and Viral Transfection/Transduction
Human cell lines were transformed and/or immortalized using standard proto-
cols. cDNAs were delivered using retroviral transduction after packaging in
HEK293T cells according to manufacturer’s protocol (Mirus). For details, see
the Supplemental Experimental Procedures.
Cell-Cycle, Chromosomal Breakage, and Cell-Survival Analyses
Analysis of cell-cycle and chromosomal breakage following treatment with
DNA-damaging agents was performed as described (Kim et al., 2011). For
cell survival assays, cells were seeded overnight and treated next day with
DNA-damaging agents. Cells were grown for 3 to 4 days, passaged at appro-
priate ratios, and counted once nearly confluent.
Western Blot and Antibodies
Whole-cell extracts were prepared by lysing cell pellets in Laemmli sample
buffer (Bio-Rad) followed by sonication. Samples were boiled and separated
on 4%–12% or 3%–8% gradient gels (Invitrogen) by SDS-PAGE. Immunoblot-
ting was performed using the following antibodies: FANCD2 (Novus NB100-
182); HA (Covance MMS-101R); UBE2T (Abcam EPR9446); and FANCI
(antibody raised in-house; no. 589).
Immunofluorescence
Cells were fixed in 3.7% formaldehyde and permeabilized with 0.5% Triton
in PBS, blocked in 5% (v/v) FBS in PBS, and incubated with antibodies
1:1,000 in blocking buffer. Cells were washed and incubated with Alexa 488
secondary antibody. Cells were washed, and coverslips were embedded




Figure 3. UBE2T Is Deficient in RA2627
(A) Comparison of normalized RNA-seq expression, fragments per kilobase of transcripts per million reads (FPKM), of known FA genes and UBE2T for RA2627
and non-FA control RA3380 primary cells. FPKM values are normalized to reflect transcript abundance and account for the variability in length of different gene
transcripts.
(B) qRT-PCR ofUBE2T expression levels in RA2627 fibroblasts (left) and RA2946 lymphoblasts (right) in comparison to wild-type control and FANCAmutant cells.
Error bars represent SE of three replicates.
(C and D) Western blot with UBE2T antibody.
(E) Schematic of the paternally derived deletion and maternally derived duplication resulting from Alu-Alu-mediated non-allelic homologous recombination
(NAHR) of AluYa5 repeats present in IVS1 and IVS6 of the UBE2T gene. For the paternal allele, recombination resulted in the loss of the sequence between the
AluYa5 repeats and one AluYa5 repeat (8,670 bp; see also Figure S1). For the maternal allele, recombination resulted in the duplication of the sequence between
the AluYa5 repeats and one AluYa5 (see also Figure S2).Next-Generation Sequencing
Indexed RNA-seq libraries were constructed using TruSeq RNA Sample Prep
Kit version 2 (Illumina). Each library was sequenced in pair-end mode using
one lane of Illumina HiSeq2000 flow cell to generate 2 3 100 bp reads. Raw
reads were aligned to the human genome (hg19) using TopHat with default
parameters. Cufflinks with GC and upper quartile normalization was then
used to calculate normalized expression levels, fragments per kilobase of
transcripts per million reads (FPKM) (Trapnell et al., 2012). WES was per-
formed as described in the Supplemental Experimental Procedures.
PCR, Reverse Transcription, and qRT-PCR Performed to Identify
UBE2T Mutations in Proband
PCR reactionswere performed using TaqDNAPolymerase (QIAGEN), Phusion
High-Fidelity PCR Master Mix with GC buffer (Thermo Scientific), and PCR
SuperMix High Fidelity (Invitrogen) according to manufacturer’s protocols,
and primers are listed in Table S4. Total mRNA was extracted using RNeasyplus kit (QIAGEN). Superscript III reverse transcriptase followed by Platinum
SYBR Green SuperMix-UDG (Invitrogen) was used according to manufac-
turer’s protocol and normalized against GAPDH. For details, see the Supple-
mental Experimental Procedures.ACCESSION NUMBERS
Genomic coordinates weremapped to GRCh38/hg38 human assembly. cDNA
coordinates were mapped against RefSeq: NM_014176.3.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and four tables and can be found with this article online at




Figure 4. UBE2T cDNA Complements RA2627 Hypersensitivity to Crosslinking Agents and Monoubiquitination of FANCD2 and FANCI
(A–C) Complementation of MMC, DEB, and cisplatin sensitivity of proband fibroblasts (RA2627). Error bars represent SD.
(D) Complementation of cell-cycle defect after 45 nM MMC treatment. Cells were treated with drug and cultured for 48 hr before analysis.
(E) Expression of wild-type HA-FLAG-tagged UBE2T cDNA or empty vector control (EV) in RA2627 fibroblasts used in experiments (A)–(G).
(F) Western blot analysis with FANCD2 and FANCI antibody of UBE2T-complemented cells with or without 24 hr 1 mM MMC treatment.
(G) FANCD2 foci formation of complemented cells following treatment with or without 1 mM MMC for 24 hr.AUTHOR CONTRIBUTIONS
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